|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicated that dual inhibition of PI3K/Akt and MEK5/ERK5 signaling was more effective at reducing the proliferation and survival of TNBCs than single inhibition of either pathway alone.
|
31464004 |
2020 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
|
31464004 |
2020 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
We show that endothelial-specific deletion of Cdc42 elicits CCM-like cerebrovascular malformations and that CDC42 is engaged in the CCM signaling network to restrain the MEKK3-MEK5-ERK5-KLF2/4 pathway.
|
30732528 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together, these findings suggest that MEK5 is a novel autophagy modulator and that this kinase could be a therapeutic target for neurodegenerative diseases such as amyotrophic lateral sclerosis.
|
31005259 |
2019 |
|
Malignant transformation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Our data revealed that MAP2K5 variants A321T or M367 T can activate MAP2K5-ERK5 pathway, alter downstream gene expression, and subsequently induce thyroid epithelial cell malignant transformation.
|
30132833 |
2019 |
|
Cavernous Hemangioma of Brain
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, CDC42 depletion in ECs elicited increased MEKK3 (mitogen-activated protein kinase kinase kinase 3)-MEK5 (mitogen-activated protein kinase kinase 5)-ERK5 (extracellular signal-regulated kinase 5) signaling and consequent detrimental overexpression of KLF (Kruppel-like factor) 2 and KLF4, recapitulating the hallmark mechanism for CCM pathogenesis.
|
30732528 |
2019 |
|
Nonmedullary Thyroid Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
|
30132833 |
2019 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of MEK5-ERK5 signaling also repressed breast cancer cell migration and invasion and substantially reduced lung metastasis without affecting primary tumor growth.
|
29713055 |
2018 |
|
Cholelithiasis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The MC4R(rs17782313) (OR 1.27, 95% CI [1.02;1.58]), MAP2K5(rs2241423) (OR 1.80, 95% CI [1.04;3.41]), NRXN3(rs10146997) (OR 1.26, 95% CI [1.01;1.57]), HHEX(rs1111875) (OR 1.29, 95% CI [1.03;1.62]), FAIM2(rs7138803) (OR 0.66, 95% CI [0.48;0.91]), and apolipoprotein E4 allele (OR 0.76, 95% CI [0.59;0.98]) were associated with gallstone disease.
|
28799434 |
2017 |
|
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of MEK5 could confer non-invasive breast cancer cells to become invasion capable cells.
|
27878304 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MEK5 overexpression is associated with the occurrence and development of colorectal cancer.
|
27160304 |
2016 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrated that MEK5 and ERK5 are overexpressed in human adenomas (P<0.01) and adenocarcinomas (P<0.05), where increased ERK5 expression correlated with the acquisition of more invasive and metastatic potential (P<0.05).
|
25855966 |
2015 |
|
Tremor
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The MAP2K5/SKOR1 marker rs12593813 was associated with higher frequency of tremor in the Tel-Aviv cohort (61.0% vs. 46.5%, p = 0.001, dominant model).
|
25817513 |
2015 |
|
Pediatric Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genetic variations in SEC16B, MC4R, MAP2K5 and KCTD15 were associated with childhood obesity and interacted with dietary behaviors in Chinese school-age population.
|
25637721 |
2015 |
|
Anxiety
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d' = 1.0, r(2) = 0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology.
|
24436253 |
2014 |
|
Anxiety Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d' = 1.0, r(2) = 0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology.
|
24436253 |
2014 |
|
Mental Depression
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d' = 1.0, r(2) = 0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology.
|
24436253 |
2014 |
|
Depressed mood
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
A predicted miR-330-3p target site SNP (rs41305272) in mitogen-activated protein kinase kinase 5 (MAP2K5) mRNA was in LD (d' = 1.0, r(2) = 0.02) with a reported GWAS-identified variant for restless legs syndrome (RLS), a disorder frequently comorbid with anxiety and depression, possibly because of a shared pathophysiology.
|
24436253 |
2014 |
|
Impulsive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In the meta-analysis data, MAP2K5 was associated with inattention, GPRC5B with hyperactivity/impulsivity and inattention and CADM2 with hyperactivity/impulsivity.
|
23533005 |
2013 |
|
Polycystic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We also identified the essential involvement of the MEK5-ERK5 pathway in the abnormal proliferation of BECs in the PCK rat.
|
23097114 |
2013 |
|
Inattention
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In the meta-analysis data, MAP2K5 was associated with inattention, GPRC5B with hyperactivity/impulsivity and inattention and CADM2 with hyperactivity/impulsivity.
|
23533005 |
2013 |
|
Hyperactive behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In the meta-analysis data, MAP2K5 was associated with inattention, GPRC5B with hyperactivity/impulsivity and inattention and CADM2 with hyperactivity/impulsivity.
|
23533005 |
2013 |
|
Polycystic Kidney - body part
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also identified the essential involvement of the MEK5-ERK5 pathway in the abnormal proliferation of BECs in the PCK rat.
|
23097114 |
2013 |
|
Kidney Failure, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the German sample, variants in MEIS1 and BTBD9 were associated with RLS in ESRD (P(nom)≤0.004, ORs 1.52 and 1.55), whereas, in the Greek sample, there was a trend for association to MAP2K5/SKOR1 and BTBD9 (P(nom)≤0.08, ORs 1.41 and 1.33).
|
21572129 |
2011 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that MEK5/ERK5 is important for FLT3-ITD induced hematopoietic transformation and may thus represent an alternative therapeutic target in the treatment of FLT3-ITD positive leukemia.
|
21820407 |
2011 |